NRC FORM 374
(10-86)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 52

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Beth Israel Hospital	In accordance with letter dated June 20, 1990,
2. 70 Parker Avenue Passaic, New Jersey 07055	3. License number 29-03047-01 is amended in its entirety to read as follows:
	4. Expiration date January 31, 1990 (extended)
	5. Docket or Reference No 030-02465

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 1000 millicuries total for sources authorized in Subitem 6.E.
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 10 millicuries of each byproduct material authorized in Subitem 6.F.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-03047-01
Docket or Reference number: 030-02465
Amendment No. 52

(6., 7., and 8. Continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Xenon 133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	G. 200 millicuries
H. Palladium 103	H. Sealed source (Theragenics Corporation Model 100)	H. 500 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. In vitro studies.
G. Blood flow and pulmonary function studies.
H. For interstitial treatment of cancer.

CONDITIONS

10. Licensed material shall be used only at 70 Parker Avenue, Passaic, New Jersey.

11. Radiation Safety Officer: Sreenivarsa Murthy, M.S.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-03047-01

Docket or Reference number: 030-02465

Amendment No. 52

(Continued) CONDITIONS

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Sam I. Brown, M.D.	Groups I, II, III, IV, V and VI In vitro studies Xenon 133 Palladium 103 for interstitial treatment of cancer
Arthur L. Siegel, M.D.	Groups I, II, III and VI Xenon 133 Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction Palladium 103 for interstitial treatment of cancer
Sehedon Lang, M.D.	Iodine 125 or iodine 131 as iodinated human serum albumin for blood volume determination
Michael L. Mund, M.D.	Strontium 90 for treatment of superficial eye conditions
Michael D. Green, M.D.	Groups I, II and III
Glenn Ross, M.D.	Groups I and II Xenon 133
Sung Il Lee, M.D.	Groups IV, V and VI Palladium 103 for interstitial treatment of cancer
Surekha D. Khedekar, M.D.	Groups I, II and III Xenon 133

13. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-03047-01

Docket or Reference number: 030-02465

Amendment No. 52

(Continued) CONDITIONS

14. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's Administrator and Radiation Safety Committee, and

    B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    C. Performs only those procedures which the physician is specifically authorized to perform pursuant to a license issued by the Nuclear Regulatory Commission.

    The licensee shall maintain for inspection by the Commission copies of the written permission specified in A. above and of the license(s) specified in B. and C. above for a period of 5 years from the date permission is granted under A. above.

15. Patients containing Iodine-131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from detector cells by the licensee.

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated September 24, 1984, containing ALARA Program
    B. Letter dated January 7, 1985
    C. Letter dated March 5, 1985
    D. Letter dated September 4, 1986
    E. Letter dated September 25, 1987
    F. Letter dated February 24, 1988
    G. Letter dated January 23, 1989
    H. Letter dated April 10, 1989
    I. Letter dated June 20, 1990

For the U.S. Nuclear Regulatory Commission

Date AUG 2 8 1990

By ORIGINAL SIGNED BY:
JEAN GRESICK-SCHUCSTA

Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 53

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Beth Israel Hospital	In accordance with letter dated December 21, 1989,
2. 70 Parker Avenue Passaic, New Jersey 07055	3. License number 29-03047-01 is amended in its entirety to read as follows:
	4. Expiration date May 31, 1996
	5. Docket or Reference No 030-02465

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 except generators	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Any diagnostic source identified in 10 CFR 35.500	E. As needed
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Iodine 125	G. Seeds	G. As needed

9. Authorized use

A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
B. Any imaging and localization procedure approved in 10 CFR 35.200.
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.
D. Any brachytherapy procedure approved in 10 CFR 35.400.
E. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
F. *In vitro* studies.
G. Treatment of superficial eye conditions.

OFFICIAL RECORD COPY ML 10

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 29-03047-01

Docket or Reference number: 030-02465

Amendment No. 53

(Continued) CONDITIONS

10. Location of use: 70 Parker Avenue, Passaic, New Jersey

11. Radiation Safety Officer: Sreenivasa Murthy, M.S

12.

Authorized Users:	Material and Use:
Sam I. Brown, M.D.	35.100; 35.200; 35.300; 35.400; 35.500 In vitro studies
Arthur L. Siegel, M.D.	35.100; 35.200; 35.400; 35.500 Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction
Sehedon Lang, M.D.	35.100; 35.500 Iodine 125 or iodine 131 as iodinated human serum albumin for blood volume determination
Michael L. Mund, M.D.	35.400; 35.500
Michael D. Green, M.D.	35.100; 35.200; 35.500
Glenn Ross, M.D.	35.100; 35.200; 35.500
Sung IL Lee, M.D.	35.300; 35.400; 35.500
Surekha D. Khedekar, M.D.	35.100; 35.200; 35.500

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material so that at no time is a quantity of radioactive material possessed in excess of a quantity which requires decommissioning funding in accordance with 10 CFR 30.35(d), 10 CFR 40.36(b) or 10 CFR 70.25(d).

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated December 21, 1989
B. Letter dated November 13, 1990
C. Letter dated May 2, 1991

For the U.S. Nuclear Regulatory Commission

Date MAY 17 1991

By Original Signed By:
Steven R. Courtemanche
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

U.S. NUCLEAR REGULATORY COMMISSION
REGION I
OPEN ITEMS TRACKING SYSTEM

DOCKET NUMBER: 30-02485

	REPORT NUMBER	STATUS	DATE OPEN	DATE CLOSED	REVIEWER NAME	OPTION	CLOSING REFER
1	89-001	OPEN	02/27/89		JENSEN	VIOL	

ITEM: FAILURE TO PERFORM A SURVEY OF A PATIENT AND ROOM AT CONCLUSION OF BRACHYTHERAPY

D1167